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Abstract
Background: Recent attempts to diminish nickel use in most industrial products have led to an
increasing utilization of alternative metal compounds for destinations such as the alloys used in
orthopaedics, jewellery and dentistry. The present study was undertaken with the aim to evaluate
the potential for an allergic response to nickel, palladium and rhodium on the basis of antigen-
specific induction of inflammatory/regulatory cytokines, and to characterize, according to the
cytokine profiles, the nature of simultaneous positive patch tests elicited in vivo.
Peripheral blood mononuclear cells (PBMC) from 40 patients with different patch test results were
kept in short term cultures in the presence of optimized concentrations of NiSO4 × 6H2O, PdCl2
and Rh(CH3COO)2. The production of IFN-γ and IL-10 elicited by metal compounds were analyzed
by the ELISpot assay.
Results: We found a specific IFN-γ response by PBMC upon in vitro stimulation with nickel or
palladium in well recognized allergic individuals. All controls with a negative patch test to a metal
salt showed an in vitro IL-10 response and not IFN-γ production when challenged with the same
compound. Interestingly, all subjects with positive patch test to both nickel and palladium (group
3) showed an in vitro response characterized by the release of IFN-γ after nickel stimulation and
production of IL-10 in response to palladium.
Conclusion: These results strongly suggest that the different cytokine profiles elicited in vitro
reflect different immune responses which may lead to the control of the allergic responses or to
symptomatic allergic contact dermatitis. The development of sensitive and specific in vitro assays
based on the determination of the cytokine profiles in response to contact allergens may have
important diagnostic and prognostic implications and may prove extremely useful in
complementing the diagnostic limits of traditional patch testing.
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Background
Allergic contact dermatitis (ACD) affects a large fraction of
the general population being most frequently elicited by
nickel (Ni), which is responsible of a delayed-type hyper-
sensitivity clinically revealed by the demonstration of
eczematous reactions upon patch testing and by labora-
tory testing of antigen-specific T-cell proliferation [1-3].
These alterations are the result of the interaction between
the metal ions, which act as haptens, and the skin surface,
thus favouring the contact and binding with cellular and
extracellular matrix proteins [4-6], and the induction of a
cellular immune response against the hapten-carrier pro-
tein complex [7,8]. Recent attempts to diminish Ni use in
most industrial products have led to an increase in the use
of different metal compounds for specific destinations
such as the alloys used in orthopaedics, jewellery and den-
tistry [9]. For instance, the use of palladium (Pd)
increased in the past 10 years [10] also due to the fact that
dentistry alloys containing Pd appear more resistant to
mechanical wearing effects [11,12]. Similarly, rhodium
(Rh), which is primarily used as an alloying agent to
harden platinum and Pd, it is now employed in electrical
material because of its low electrical and contact resist-
ance, in jewellery (platings of silver or white gold because
of its silvery white colour), in optical instruments and
dental prostheses.
Nevertheless, it has been recently recognized that also
exposure to metal ions such as Pd, chromium, cobalt and
gold, can induce a cellular immune response and clinical
manifestations of ACD, even if less frequently than Ni
[13-15]. In fact, positive patch testing to PdCl2 and clinical
manifestation of ACD to Pd have been described with
increasing frequency [16,17]. Despite its low sensitization
potential, also Rh has been reported as sensitizer in the
form of salt [18].
In Ni sensitized subjects a simultaneous patch test reactiv-
ity to Pd has been frequently reported [19,20] and a dou-
ble sensitization can be hypothesised especially in
individuals wearing dental prosthesis. Nevertheless, a
cutaneous cross-reactivity cannot be excluded for the
chemical and structural similarities of Ni and Pd [21].
Metal ions are incomplete antigens which have to bind to
endogenous peptides to be "visible" to the immune sys-
tem [7] and Ni and Pd encountering the same cellular
environment might form in vivo complexes with similar
proteins thus eliciting cross-recognizing immune
responses [17]. Moreover, two independent in vitro stud-
ies demonstrated an immunologic cross reactivity
between these metals at the T cell clonal level [22,23].
Identifying both a double sensitization and a lymphocyte
cross-reactivity to different metal ions in vivo is an impor-
tant issue for clinicians in directing the choice of implant
materials in order to avoid incompatible reactions. Con-
sequently, the diagnosis of ACD to both Ni and Pd needs
in vitro assays complementary to patch testing [24,25].
Indeed, the variability of the readouts obtained with patch
testing have stimulated a number of studies aimed at
developing assays characterizing the immune response to
metal salts. Recently, Minang et al. [26] analyzed the dif-
ferent cytokine profiles induced by nickel in allergic or tol-
erant subjects by enzyme-linked immunospot (ELISpot)
assay. In fact, the sensitivity and specificity of the ELISpot
assay allow the measurement of very low frequencies of
cytokine-producing cell, therefore offering a powerful tool
for the detection and characterization of Ni sensitization
with important implications for diagnostic strategies
[27,28].
The present study was undertaken with the aim to evalu-
ate the potential of the ELISpot assay in determining sen-
sitivities to Ni or Pd and to Ni and Pd on the basis of
specific induction of inflammatory/regulatory cytokines.
Since all subjects were skin challenged to Ni, Pd and Rh
salts, and none of them had positive skin reactivity to Rh,
this metal was employed to assess the cytokine profile in
non allergic subjects and to explore the possibility to iden-
tify a cellular immunity against materials with traces of
heavy metals.
Results
Patch tests
To analyse the cytokine response to metals, we considered
four different groups of subjects according to their skin
responses. As summarized in Table 1, group 1 included 10
patients with a strong positive reaction to Ni; group 2
included 10 patients with strong (n = 7) or moderate (n =
3) hypersensitivity to Pd; group 3 included 10 patients
showing a strong reactivity to Ni and a simultaneous weak
(n = 4) or moderate (n = 6) response to Pd; and, finally,
group 4 included 10 patients with negative patch testing
to all metals investigated. All patients enrolled in the
study (n = 40) had a negative patch test response to Rh.
IFN-γ and IL-10 production by PBMC in response to Ni, Pd 
and Rh
To determine the production of IFN-γ and IL-10 upon in
vitro  stimulation, PBMC from patients with different
patch test results were kept in short term cultures in the
presence of NiSO4 × 6H2O, PdCl2 and Rh(CH3COO)2 and
analyzed by the ELISpot assay.
IFN-γ and IL-10 basal response or elicited by metal salts or
PHA in PBMC from different groups of patients are shown
in Figure 1. The primary readouts of spot forming cells for
each experimental condition in individual patients are
also shown in Table 2.BMC Immunology 2008, 9:19 http://www.biomedcentral.com/1471-2172/9/19
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PHA stimulated cultures invariably showed increased
numbers of IFN-γ or IL-10 producing cells with Indexes
ranging from 6.8 to 8.3, and the values did not signifi-
cantly differ among the different groups, therefore exclud-
ing differences in the capability of different subjects to rise
a specific cytokine response or impairment of cellular
function due to cryopreservation.
Remarkably, IFN-γ releasing cells upon metal stimulation
were the most represented in strict association with results
of the in vivo responses. In fact, IFN-γ-Ni responsive cells
(Index > 3) were detected in subjects with positive patch
test to Ni either alone (group1) or in association with
moderate or weak response to Pd (group 3) (P = 0.28).
IFN-γ-Pd responsive cells were detected only in subjects
with strong or moderate Pd positive patch testing (group
2), and not in subjects with moderate or weak in vivo
response to Pd associated with a strong Ni reactivity
(group 3) (P < 0.0001).
All subjects with negative patch test results showed an in
vitro IL-10 production upon metal stimulation while any
positive or ambiguous IFN-γ response to Ni, Pd or Rh was
present. Interestingly a different in vitro behaviour was
found between subjects showing a monosensitization to
Pd and subjects with concomitant skin reactivity to Pd
and Ni. In fact, these subjects (group 3) had an in vitro
reactivity more similar to Ni monosensitized patients
(IFN-γ-Ni responsive cells: P = 0.28; IL-10-Ni responsive
cells: P = 0.19) rather than to Pd monosensitized subjects
(IFN-γ-Ni responsive cells P < 0.0001; IL-10-Ni responsive
cells: P < 0.0001).
Overall results showed that IL-10 producing cells in
response to metals were invariably associated to a lack of
IFN-γ production. This is well visualized by the scatter
plots (Figure 2) of individual Index values obtained in
response to Ni or Pd in all groups of patients, where it can
be appreciated that IFN-γ or IL-10 production in response
to metal salts are mutually exclusive, while PHA is capable
of inducing both cytokines. Statistical analysis confirmed
the significant negative correlation between IFN-γ and IL-
10 production (P < 0.0001). The same diagram (Figure 2)
reporting the individual responses in the different group
of patients also shows that the in vivo moderate and weak
reactivity to Pd, observed in association to strong reactiv-
ity to Ni (group 3), did not match the in vitro response,
that was clearly sustained by IL-10 rather than IFN-γ pro-
ducing cells.
Discussion
In the present study, we have investigated the profiles of
cytokine production by PBMC of ACD patients and
healthy controls in response to the well known contact
allergens Ni and Pd, or to Rh, considered to have a low
sensitization potential, through the ELISpot assay.
The results showed that PBMC from well recognized aller-
gic individuals affected by ACD have a higher frequency of
IFN-γ releasing cells upon in vitro stimulation with Ni or
Pd, as compared to control groups. Most interestingly, we
found that PBMC from all the individuals exhibiting a
negative skin response to a metal salt (group 4) revealed a
clear IL-10 response when challenged with the same
metal, in the absence of any detectable IFN-γ response.
Accordingly, all subjects included in the study had a neg-
ative skin response to Rh, which was invariably associated
to Rh-induced IL-10 production in vitro.
The immunologic mechanisms responsible for the clinical
hypersensitivity towards metals have been recently
reviewed [7]. It is known that Ni-specific, IFN-γ-producing
CD4+ and CD8+ T cells are major effectors of sensitization
and directly responsible for skin manifestations [6,29],
whereas IL-10 and TGF-β-secreting regulatory T cells are
thought to down-modulate the response [2,30,31]. The
deleterious expansion of Ni-specific, effector CD8+ T cells
might be thus prevented by regulatory mechanisms,
including those induced by hapten-specific suppressor T
cells [32]. In humans IL-10 has been identified as a potent
anti-inflammatory cytokine produced by both Th1 and
Th2 CD4+ T cells [33], which inhibits T cell proliferation
Table 1: Characteristics of patients and healthy controls.
Group Subject n. Sex Age range (median) Patch test to Ni Patch test to Pd Patch test to Rh
1 n = 10 9 F 28 – 40 (30) 9 +++ 9 - 9 -
1 M 30 1 +++ 1 - 1 -
2 n = 10 9 F 28 – 38 (33) 9 - 7+++/2 ++ 9 -
1 M 40 1 - 1 ++ 1 -
3 n = 10 9 F 29 – 40 (32) 9 +++ 6 ++/3 + 9 -
1 M 39 1+++ 1 + 1 -
4 n = 10 9 F 28 – 38 (33) 9 - 9 - 9 -
1 M 36 1 - 1 - 1 -
As described in the methods, patch test reactivity to the different metal salts was defined as strong (+++: oedema, erythema, papules and vesicles), 
moderate (++: oedema, erythema and papules), weak (+: oedema and erythema) or no reaction (-).BMC Immunology 2008, 9:19 http://www.biomedcentral.com/1471-2172/9/19
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Cytokine response elicited by metals or PHA by ELISpot analysis Figure 1
Cytokine response elicited by metals or PHA by ELISpot analysis. Elispot results of detection of IFN-γ or IL-10 pro-
ducing PBMC upon stimulation with Ni (20 μg/ml), Pd (2.5 μg/ml), Rh (5 μg/ml) or PHA (1 μg/ml) were expressed as Index val-
ues. Index is expressed by the ratio between the number of spot forming cells (IFN-γ and IL-10 producing PBMC) upon 
stimulation with metal salts and those present in the absence of stimuli (spontaneous cytokine production). The mean values of 
Index values ± SD were obtained for the 4 different groups of 10 subjects according to their in vivo reactivity to metal salts. 
Cytokine producing cells in control triplicate wells with medium alone was the baseline value (Index = 1). Panel A: patch test 
positive to Ni (group 1); B: patch test positive to Pd (group 2); C: patch test positive to Ni and Pd (group 3); D: negative patch 
test (group 4). The statistical analysis between IFN-g and IL-10 producing cells upon stimulation with Ni or Pd between 
patients belonging to group C and A or B was performed using the Mann-Whitney test. The highly significant differences (P < 
0.0001), found between group C and B, are indicated by symbols (*, **, °, °°).BMC Immunology 2008, 9:19 http://www.biomedcentral.com/1471-2172/9/19
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Table 2: Individual values of spot forming cells for each experimental condition expressed as mean values and Standard Errors of 
triplicate wells.
IFN-γ IL-10
Subject n. Mean
Std. Error
W/O PHA Ni Pd Rh W/O PHA Ni Pd Rh
Patch test positive to Ni 1 Mean 18,67 151 116 14,33 5,667 19 132 36 79,67 76
(Group 1) Std. Error 2,404 4,359 3,055 1,202 0,8819 0,5774 3,606 2,082 3,93 3,786
2 Mean 25,17 164,3 150 29,33 17,67 21 157,3 36,5 73 86,33
Std. Error 1,74 6,766 3,215 2,333 1,453 2,082 6,36 0,2887 2,309 2,333
3 Mean 27,67 203 136,5 19,33 16,67 11,67 92 22,5 47 52
Std. Error 2,333 3,606 0,866 0,8819 1,453 0,8819 3,606 1,443 3,606 2,887
4 Mean 26,67 203 168,3 18,67 5,333 33,33 270 62,67 51,33 132,7
Std. Error 2,404 9,074 3,48 1,202 1,202 1,202 6,351 6,333 1,667 5,207
5 Mean 30,67 246,7 168,3 27,33 27,33 38 289 65,33 143,3 147,7
Std. Error 0,8819 1,856 2,603 0,8819 1,764 2,517 6,083 2,603 2,963 7,311
6 Mean 13,33 100,3 53 25 6,667 22 177 32,67 79,33 93,67
Std. Error 2,186 3,18 3,055 1,732 1,202 5,568 6,658 2,906 0,8819 4,667
7 Mean 21,33 171,7 119,3 10,83 10,5 21,67 147,3 35,67 85,33 91
Std. Error 0,3333 3,667 4,667 0,6009 0,2887 2,848 5,925 3,283 2,603 2,082
8 Mean 20 158 129,3 10,33 15,5 35 265,7 46,5 136 132,7
Std. Error 1,155 3,464 3,18 1,764 1,443 2,309 11,98 0,866 6,245 5,487
9 Mean 20,67 160,7 118,3 4,333 8,333 33,5 233 59 129,3 130
Std. Error 1,764 5,239 4,41 1,453 1,453 0,866 7,506 2,887 5,783 3,215
10 Mean 13,33 105,3 65 14,67 2,667 15,5 107,7 25,33 59 62
Std. Error 2,404 5,696 2,082 1,453 1,202 1,607 3,844 3,844 2,082 1,732
Patch test positive to Pd 11 Mean 10 69,33 11 45,33 2,333 27 197,3 84,33 21 129,3
(Group 2) Std. Error 1,155 3,48 0,5774 2,603 1,333 2,887 7,219 2,404 3,606 3,18
12 Mean 14,33 100,3 20,67 83,67 15,67 16,5 124,7 58,67 10,33 68,33
Std. Error 3,844 1,453 2,333 4,631 1,202 1,443 3,283 1,202 2,603 2,906
13 Mean 13 92 19,33 62,33 14 37,67 285 143 38 186
Std. Error 3,215 5,686 2,028 3,844 1,528 1,453 5,508 2,309 1,732 3,464
14 Mean 13,5 101 17 71,67 10,67 35,5 285 127,7 30 151
Std. Error 0,866 7,937 3,215 2,333 0,8819 0,2887 5,508 4,41 1,155 1,528
15 Mean 45 360,3 41 229,7 36,33 9,333 73,67 37,67 10,67 41,33
Std. Error 1,732 9,351 1,732 2,906 3,48 1,764 2,728 1,202 1,764 1,856
16 Mean 6,5 53 5,667 34 2 12 92 47,33 13,67 45,33
Std. Error 1,443 2,082 1,202 1,155 1,528 1,528 2 1,856 1,764 1,764
17 Mean 15,67 117,3 9,667 72,67 6,333 23,33 190 84 22 93
Std. Error 3,48 7,688 0,6667 1,453 0,8819 2,848 2,082 2,082 2,309 1,155
18 Mean 6,667 52 5,333 32 2 28,67 198,3 110,3 24 112
Std. Error 1,764 3,512 0,8819 2,082 1 1,856 10,4 9,171 1,155 7,371
19 Mean 32,67 273 36 170,3 13,33 10,33 70,33 34,33 9,667 44
Std. Error 1,202 3,606 2,646 5,548 1,202 0,8819 2,728 3,283 1,202 2,646
20 Mean 30,67 244 24,33 153,3 7 28,67 197,3 120,7 31,67 116
Std. Error 1,202 4,509 2,028 2,848 1,528 2,404 2,333 8,95 1,764 4,041
Patch test positive to Ni 
and Pd
21 Mean 14 105,7 89,67 17,67 10,67 20,33 153,7 32,67 72,33 81
(Group 3) Std. Error 2,646 8,293 6,692 2,404 1,764 1,453 5,783 3,528 2,333 3,786
22 Mean 24,83 172 150 25 25 22 176 26,67 79,67 93,67
Std. Error 2,048 3,786 3,464 2,082 2,887 5,568 6,658 3,283 2,333 2,603
23 Mean 26,67 203,7 157 37,33 14,67 38,67 292,3 66,67 148,7 152
Std. Error 1,453 8,686 4,619 2,333 1,764 2,186 5,783 1,856 4,055 3,606
24 Mean 31 247 186 30,67 18,33 23,67 186,3 21,33 94,67 119,3
Std. Error 1,155 2,309 3,464 1,453 2,028 4,702 7,623 3,528 4,41 1,856
25 Mean 25,67 197 157,7 22,33 18 37,33 285 49 145,7 143
Std. Error 1,764 4,041 1,856 2,028 2,309 1,453 5,508 3,215 3,383 3,215
26 Mean 20 157,7 117 16 10 15,5 125,3 29,67 56 61,67
Std. Error 1,155 3,18 2,082 1,155 2,517 0,2887 4,667 1,667 2,887 1,764BMC Immunology 2008, 9:19 http://www.biomedcentral.com/1471-2172/9/19
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of both subsets, and regulates the development of Th1
cells by blocking IL-12 driven Th1 responses [34]. IL-10 is
thought to exert its effects by down-regulating the expres-
sion of co-stimulatory molecules required for appropriate
antigen presentation [35]. Ferguson TA et al and Schwarz
A et al [36,37] demonstrated a key regulatory role for IL-
10 in both the induction and the effector phases of
murine contact hypersensitivity. Our results provide evi-
dence supporting the hypothesis that a regulatory mecha-
nism mediated by IL-10 contributes to the control of
hypersensitivity in response to Ni, Pd and Rh therefore
contrasting the development of ACD. Even if the protec-
tive role of IL-10 is well established, studies addressing the
cytokine profile in subjects with or without ACD have
been partly contradictory [26,31,38]. It should be consid-
ered that different protocols used for the in vitro stimula-
tion or the different sensitivities of the immunoassays for
IL-10 measurements could be responsible for the different
results obtained.
The finding that not only Ni but also other metals could
elicit a response in PBMC from sensitized subjects [15],
was not surprising and prompted us to explore the profile
of cytokine production in patients which scored negative
at patch testing toward Pd and Rh, which are present in
several synthetic materials including new metallic alloys
[39,40]. Remarkably, we found very clear-cut, divergent,
IL-10 "protective" or IFN-γ "reactive" profiles in patients
showing a negative or positive skin reactivity to metal salts
(group 1, 2, 4), respectively. Moreover, all the subjects
with positive patch test to both Ni and Pd (group 3)
showed an in vitro response similar to monosensitized
patients to Ni, characterized by the release of IFN-γ after
Ni stimulation and production of IL-10 in response to Pd
or Rh. Interestingly, comparing the cytokine response to
Pd, subjects with the same patch test reactivity (n = 3: ++
in the group 2; n = 6: ++ in the group 3) displayed a
reversed profile (Table 2). On the basis of these data, it is
conceivable that a positive (IFN-γ) response in vitro may
predict the development of adverse reaction to prosthesis
alloys or to chemotherapeutic agents containing toxic
metals. In fact, previous studies on multiple sensitivities
to transition metals reported that the majority of Ni/Pd
reactions occurred without clinical evidence of Pd sensiti-
zation [10,19,41].
We analyzed the IFN-γ response in patients with an unam-
biguous Ni patch test reaction (group 1 and 3 patients
with +++ reactions) to provide positive controls for the in
vitro assay, in order to define optimal conditions for anti-
27 Mean 12,33 95,67 70,33 12 9,667 30,33 210,7 39,67 114,7 118,3
Std. Error 1,453 10,37 3,383 1,528 2,028 3,18 6,984 4,978 3,48 3,756
28 Mean 45 361 244,3 49,67 52,67 31,67 215 50 124,7 133
Std. Error 1,732 9,292 4,096 3,283 2,333 2,963 5,132 2,646 3,48 2,309
29 Mean 45,5 373,3 285 60 40 38,33 264,3 72,67 161,7 153,3
Std. Error 2,021 2,963 6,429 1,732 3,512 4,055 12,25 2,028 4,055 3,48
30 Mean 15,67 118 96 6,333 16,33 33,67 254,3 54 132 131,3
Std. Error 2,333 3,215 6,928 2,028 2,728 2,963 8,413 2,309 5,292 2,963
Patch test negative 31 Mean 3,667 24 6 4,667 4,667 32,33 243 146,7 116,7 134,3
(Group 4) Std. Error 0,8819 1,528 1,155 0,8819 1,202 2,028 4,041 4,631 6,173 5,608
32 Mean 17,33 130 27,67 21,33 33 47,33 377 237,3 181 201,3
Std. Error 2,333 2,887 1,764 3,283 1,732 2,728 2,646 2,603 3,215 6,064
33 Mean 6,667 53,33 10,33 4,333 5,667 18,33 140,3 69,67 66,33 90,67
Std. Error 1,202 2,728 0,8819 1,453 0,6667 1,453 2,603 2,404 4,842 4,631
34 Mean 11,33 82,67 15 8 8 24,33 193,3 98 99 108
Std. Error 0,8819 2,333 2,082 1,732 1,528 1,202 3,844 1,732 4,619 5,196
35 Mean 14,33 112,7 17,33 18,67 7,333 34,33 260,3 134 111,7 132
Std. Error 1,202 5,044 1,453 2,028 0,8819 2,404 3,18 1,528 4,41 4,359
36 Mean 3 23 3,333 0,6667 2,333 17 138 78,33 83 67,67
Std. Error 0,5774 1,528 1,453 0,6667 0,3333 2,646 4,163 1,453 3,055 2,404
37 Mean 18 141 23,33 7,333 4,333 15 109,7 57,33 57,33 58,67
Std. Error 1,732 5,033 1,453 1,202 0,8819 1,732 2,906 2,404 3,18 4,256
38 Mean 22,67 180,7 27,33 18,33 11,67 29 196,7 154,3 114,3 122,7
Std. Error 1,202 1,202 2,404 1,453 1,202 1,732 1,453 2,404 6,009 4,41
39 Mean 6,667 54 6,333 2 5,333 10 71,33 52,67 40,33 40,33
Std. Error 1,202 2 0,8819 1,155 1,856 1,155 2,028 2,028 2,906 4,096
40 Mean 13,33 105,3 10,67 11 15 27,67 199,3 146,3 107,7 107
Std. Error 1,453 3,712 0,8819 1,528 1,528 1,453 3,756 11,26 4,978 7
Patients were grouped following their patch test reactions. W/O: medium alone; PHA: polyclonal stimulation; Ni 20 μg/ml, Pd 2.5 μg/ml, Rh 5 μg/ml.
Table 2: Individual values of spot forming cells for each experimental condition expressed as mean values and Standard Errors of 
triplicate wells. (Continued)BMC Immunology 2008, 9:19 http://www.biomedcentral.com/1471-2172/9/19
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gen-specific cytokine production and to offer a highly sen-
sitive and specific test suitable for clinical determinations.
On the basis of this setting, stimulation values greater
than 3 to 7 were commonly obtained with metal salts or
with lectin (PHA) polyclonal stimulation, respectively,
suggesting that cryopreservation did not affect the
cytokine response of lymphocytes, as sustained by the
study from Kreher et al [42].
The data gathered by the ELISpot analysis did not show
any cross-reactivity of T-cells neither the co-existence of T
cell clones with differential responsiveness. Since any Ni
contamination was demonstrated in the Pd salt used for
patch testing (data not shown), it is presumable that an
immunologic cross-reactivity based on molecular mim-
icry among different hapten-carrier complexes might take
place in vivo, at the skin level. Due to their small size,
metal ions are incomplete antigens which have to bind to
carrier molecules, which, in turn, are capable to capture
metal ions, and shuttling this complex to the epidermal
basement membrane [4,7]. On the other hand, the con-
comitant reactivity to Ni and Pd, observed in a number of
patients by skin testing could concern also the possibility
of a delayed or impaired response of skin regulatory cells.
A dysfunction in T-regulatory cell can lead to an immune
activation often associated with the clinical expression of
skin diseases such as atopic dermatitis and psoriasis [43].
Experimental data suggested also the possibility that, in
analogy to superantigens, Ni or Pd may also directly link
TCR and MHC in a peptide independent manner and can
effectively amplify the hapten-specific immune response
[44,45]. It is also known that a strong binding of different
superantigens to the TCR could render T cells insensitive
to suppression by CD4+CD25+ Treg cells [46] and IL-10
[47].
Knowledge about the immunologic mechanism responsi-
ble for ACD is still fragmentary. It is accepted that the sen-
sitising chemical penetrates into the epidermis, and,
depending on its properties, it "perturbates" the environ-
ment. However, neither the molecular nature of Ni-
induced antigenic determinants nor the very early molec-
ular events of metal transport through the human epider-
mis to Langerhans cells have yet been satisfactorily
resolved indicating that still many aspects of metal allergy
remain unclear.
Conclusion
Taken together, these results demonstrate that different
cytokine profiles elicited in vitro can reflect different
immune responses in vivo in ACD. The development of
sensitive and specific in vitro assays based on cytokine
response could be extremely useful in complementing
patch testing for the clinical diagnosis and characteriza-
tion of metal sensitization.
Methods
Patients
Fourty patients (n = 36 female (f)/4 male (m); mean age
33.3 yrs, range between 28–41) attending the Department
of Allergy of this Institute were enrolled in the study.
Scatter plot analysis of individual IFN-γ and IL-10 induction by  PHA, Ni or Pd in the different group of patients Figure 2
Scatter plot analysis of individual IFN-γ and IL-10 induction by 
PHA, Ni or Pd in the different group of patients. PHA induces 
PBMC release of both IFN-γ and IL-10 in all subjects, while metal salts 
induces IFN-γ or IL-10 production according to the in vivo positive or neg-
ative response. IFN-γ or IL-10 production was alternatively produced and 
consequently a highly significant negative correlation was found (Spearman 
analysis P < 0.0001). Panel A: IFN-γ and IL-10 induction (Index) by PHA or 
Ni salt; B: IFN-γ and IL-10 induction (Index) by PHA or Pd salt. Red Dia-
mond: Group 1 (induced by Ni in panel A or by Pd in panel B), Green diamond: 
Group 2 (induced by Ni in panel A or by Pd in panel B), Blue square: Group 3 
(induced by Ni in panel A or by Pd in panel B), Grey circle: Group 4 (induced by 
Ni in panel A or by Pd in panel B), Yellow triangle: Overall subjects (induced by 
PHA).BMC Immunology 2008, 9:19 http://www.biomedcentral.com/1471-2172/9/19
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Patient assessment was primarily based on a detailed
medical history, including history of metal exposure.
Wearing of metal dental braces was also recorded. None
of the patients had recently used immunosuppressive
medication, underwent UV radiation or suffered from
acute inflammatory skin diseases. The study received the
approval from the Internal Ethic Committee of Istituti
Fisioterapici Ospitalieri (San Gallicano, IFO, Rome), and
an oral informed consent was obtained from all subjects
prior to the in vitro study.
Patch testing
Patch testing was performed with all patients enrolled in
the study. The skin patch tests were with the European
standard series of contact allergens (Hermal Trolab, Rein-
beck, Germany), including 5% Nickel Sulphate hexahy-
drate (NiSO4  × 6H2O) applied in petrolatum, and
supplemented with 1% Palladium Chloride (PdCl2)
applied in petrolatum and 1% Rhodium Acetate
Rh(CH3COO)2 in aqueous solution. These salts were from
Merck (AG, Darmstadt, F.R.G). The patch tests were per-
formed by applying Finn Chambers with haptens on
unaffected skin of the upper backs of the subjects for 48 h.
Patch test responses were examined on day 2 and defined
as strong (+++: oedema, erythema, papules and vesicles),
moderate (++: oedema, erythema and papules), weak (+:
oedema and erythema) or no reaction (-) according to the
International Contact Dermatitis Research Group guide-
lines [48].
ELISpot assay
Peripheral blood mononuclear cells
PBMC were isolated from 5 to 10 ml of heparinized
blood, collected 48 hrs after skin testing, by standard
Ficoll density-gradient centrifugation (Lympholyte-H
solution Cederlane, Ontario, Canada) and washed twice
with PBS. Cell aliquots were frozen in 90% heat inacti-
vated Fetal Bovine Serum (FBS, Euroclone) and 10%
DMSO (Dimethylsulphoxide, Sigma) and kept in liquid
nitrogen until tested for ELISpot assay.
Metal salts used for in vitro cytokine assay
The metal salts used for in vitro assays were: nickel sul-
phate hexahydrate NiSO4 × 6H2O, palladium chloride
(PdCl2) and rhodium acetate Rh(CH3COO)2 (Merck AG,
Darmstadt, F.R.G). Before use, metals were resuspended
in sterile saline solution at 2 mg/ml (Bioindustria, Novi
Ligure, Italy). These stock solutions were found negative
for LPS contamination (Limulus  assay, BioWhittaker,
Cambrex Company, USA).
Definition of optimal metal salt concentrations for antigen-specific 
cytokine production
Preliminary experiments were performed in order to
determine the optimal concentration of each metal salt
for IL-10 or IFN-γ producing cells induction, measured by
ELISpot assay. Briefly, 3.5 × 105 PBMC/well from 5 non-
allergic donors were stimulated with 10 μg/ml of phyto-
haemagglutinin (PHA, Sigma, Saint Louis, Missouri, USA)
in the presence of different metal salts at concentrations
ranging from 0.1 μg/ml to 100 μg/ml. Metal salt concen-
trations > 50 μg/ml, > 25 μg/ml and > 30 of Ni, Pd and Rh
respectively inhibited the PHA-induced cytokine produc-
ing cells by 25%, and were considered toxic in agreement
with other authors (15). Subsequent preliminary experi-
ments showed that 20 μg/ml NiSO4 or 2.5 μg/ml PdCl2
yielded the higher frequency of IFN-γ producing cells in
five subjects with clinical diagnosis of ACD caused by Ni
(n = 3) or Pd (n = 2) respectively. While, PBMC from five
healthy controls cultured at the same experimental condi-
tions provided the higher frequency of IL-10 producing
cells. Also the Rh(CH3COO)2 concentration of 5 μg/ml
was chosen on the basis of the higher frequency of IL-10
producing cells in patients as well as controls.
Pre-incubation with metals
For the detection of IFN-γ, PBMC (3.5 × 105/well) were
pre-incubated with or without metals in round bottom
polypropylene tubes (Becton Dickinson Labware) in com-
plete medium (RPMI 1640, 10% FBS, 1% Penicillin-Strep-
tomycin-L-Glutamine; GIBCO-BRL, UK) for 20 hrs at
37°C and 5% CO2 in humidified air. Then cells were
transferred to the ELISpot plates and incubated for a fur-
ther 48 hrs.
ELISpot assays were performed as previously described
[49] with minor modifications. Briefly, Polyvinylidene
difluoride-backed 96-well microtiter plates (MAIPS4510;
Millipore Sunnyvale, CA, USA) were coated overnight at
4°C with 100 μl/well of specific capture antibody anti-
IFN-γ or anti-IL-10 (10 μg/ml, 100 μl/well, Endogen
Woburn, MA) dissolved in phosphate buffered saline
(PBS).
Ab-coated plates were then washed three times and incu-
bated 1 h at 37°C with complete medium to prevent non-
specific protein binding. PBMC were plated at 3.5 × 105/
well, to a final volume of 200 μl/well of complete
medium. Three different concentrations of NiSO4 (5–10–
20 μg/ml), PdCl2 and Rh(CH3COO)2 (2.5–5–10 μg/ml)
were added in triplicate wells and plates were kept in a
humidified atmosphere with 5% CO2 at 37°C. Control
triplicate wells contained PBMC with medium alone or
with phytohaemagglutinin (PHA 1 μg/ml, Sigma, Saint
Louis, Missouri, USA). After 48 hrs for IFN-γ and 72 hrs
for IL-10 detection, cells were lysed with ice-cold distilled
water, and cells were removed by 4 rinses with PBS/0.05%
Tween® 20 (Sigma, St Louis, MO, USA). After a 90 min
incubation with biotin labeled anti-IFN-γ or anti-IL-10
detection antibodies (1 μg/ml, 100 μl/well, EndogenBMC Immunology 2008, 9:19 http://www.biomedcentral.com/1471-2172/9/19
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Woburn, MA), HRP-Streptavidin-alkaline phosphatase
(Euroclone, PBS 1% BSA) was added to the wells at a dilu-
tion of 1:1000 for 30 min at 37°C in the dark. Subsequent
to specific substrate addition, the red spots were devel-
oped using AEC-chromogen solution (Sigma, St Louis,
MO, USA) and analysed by the Automated ImmunoSpot
Image Analyzer Software (AELVIS Tecnologies, TEMA
ricerche, Italy). The results were expressed as the ratio
(Index) between the number of spot forming cells
detected upon stimulation and those present in the
absence of stimuli. A positive response is defined by an
Index > 3.
Statistical analysis
The Mann-Whitney (MW) rank sum test was used to com-
pare the cytokine responses between two different groups
of patients. To evaluate the correlation between IFN-γ and
IL-10 producing cells, the Spearman rank coefficient r was
considered. A P value < 0.05 was considered to be statisti-
cally significant. Statistical analysis was performed with
GraphPad Software, version 4.00 (San Diego California
USA).
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